Lantern Pharma’s LP-184 Gains the US FDA’s Fast-Track Designation for Treating Glioblastoma
Shots:
- The US FDA has granted FTD to LP-184, developed using RADR AI platform, for treating GBM. The company plans to use RADR for exploring LP-184 in combinations to control cancer progression
- LP-184 is in P-IA assessment to find its safety, tolerability & MTD for various tumors, incl. GBM. Lantern will advance it as STAR-001 (via its subsidiary Starlight Therapeutics) for GBM plus other brain & CNS cancers after finding MTD
- The P-Ib/IIa study to evaluate the safety, PK & preliminary efficacy of LP-184 alone & in addition to spironolactone for rGBM is planned in late 2024 or early 2025. DNA damage markers, EGFR expression, MGMT status & DNA repair pathways will be analyzed as potential response predictors to plan future studies
Ref: Lantern Pharma | Image: Lantern Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
